Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: The SHR strain
Valéria de Almeida, Fernanda Fiel Peres, Raquel Levin, et al.
Schizophrenia Research (2014) Vol. 153, Iss. 1-3, pp. 150-159
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Cathrin Rohleder, Juliane Müller, Bettina Lange, et al.
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 91
Multifunctional TRPV1 Ion Channels in Physiology and Pathology with Focus on the Brain, Vasculature, and Some Visceral Systems
Maksim V. Storozhuk, Olesia F. Moroz, Alexander V. Zholos
BioMed Research International (2019) Vol. 2019, pp. 1-12
Open Access | Times Cited: 74
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Marc Fakhoury
Molecular Neurobiology (2016) Vol. 54, Iss. 1, pp. 768-778
Closed Access | Times Cited: 70
Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
Fernanda Fiel Peres, Raquel Levin, Mayra Akimi Suiama, et al.
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 68
Capsaicin and Its Effect on Exercise Performance, Fatigue and Inflammation after Exercise
Gaia Giuriato, Massimo Venturelli, Alexs A. Matias, et al.
Nutrients (2022) Vol. 14, Iss. 2, pp. 232-232
Open Access | Times Cited: 28
Endocannabinoids and Mental Disorders
Tiziana Rubino, Erica Zamberletti, Daniela Parolaro
Handbook of experimental pharmacology (2015), pp. 261-283
Closed Access | Times Cited: 63
Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia
Fernanda Fiel Peres, Mariana Cepollaro Diana, Raquel Levin, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 48
Therapeutic potential of pharmacological agents targeting TRP channels in CNS disorders
Pavan Thapak, Bhupesh Vaidya, H.C. Joshi, et al.
Pharmacological Research (2020) Vol. 159, pp. 105026-105026
Closed Access | Times Cited: 40
Endocannabinoid system alterations in Alzheimer’s disease: A systematic review of human studies
Alex J. Berry, Olga Zubko, Suzanne Reeves, et al.
Brain Research (2020) Vol. 1749, pp. 147135-147135
Open Access | Times Cited: 37
Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies
Vamsi Reddy, Dayton Grogan, Meenakshi Ahluwalia, et al.
The EPMA Journal (2020) Vol. 11, Iss. 2, pp. 217-250
Open Access | Times Cited: 34
Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research
Rafael Naime Ruggiero, Matheus Teixeira Rossignoli, Jana Batista De Ross, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 36
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
Cássio Morais Loss, Lucas Teodoro, Gabriela Doná Rodrigues, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 23
Capsaicin alleviates neuronal apoptosis and schizophrenia-like behavioral abnormalities induced by early life stress
Shilin Xu, Keke Hao, Ying Xiong, et al.
Schizophrenia (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia
Helena K. Kim, Vanessa F. Gonçalves, M. Ishrat Husain, et al.
Psychiatry Research (2023) Vol. 330, pp. 115563-115563
Closed Access | Times Cited: 8
Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy
Fernanda Fiel Peres, Raquel Levin, Valéria de Almeida, et al.
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 26
The Influence of the CB1 Receptor Ligands on the Schizophrenia-Like Effects in Mice Induced by MK-801
Marta Kruk-Słomka, Barbara Budzyńska, Tomasz Słomka, et al.
Neurotoxicity Research (2016) Vol. 30, Iss. 4, pp. 658-676
Open Access | Times Cited: 24
Neurobehavioral Profiles of Six Genetically-based Rat Models of Schizophrenia- related Symptoms
Ignasi Oliveras, Toni Cañete, Daniel Sampedro-Viana, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 9, pp. 1934-1952
Open Access | Times Cited: 7
Involvement of the TRPV1 receptor and the endocannabinoid system in schizophrenia
Junjie Huang, Huan Huang, Moyin Liu, et al.
Brain Research Bulletin (2024) Vol. 215, pp. 111007-111007
Open Access | Times Cited: 2
The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice
Marta Kruk-Słomka, Izabela Banaszkiewicz, Grażyna Biała
Neurotoxicity Research (2017) Vol. 31, Iss. 3, pp. 410-420
Open Access | Times Cited: 24
Young spontaneously hypertensive rats (SHRs) display prodromal schizophrenia-like behavioral abnormalities
Suzy Tamie Niigaki, Fernanda Fiel Peres, L.B.T. Ferreira, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018) Vol. 90, pp. 169-176
Open Access | Times Cited: 23
Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit
Valéria de Almeida, Raquel Levin, Fernanda Fiel Peres, et al.
Neuropharmacology (2019) Vol. 155, pp. 44-53
Closed Access | Times Cited: 20
Cannabinoids and glial cells: possible mechanism to understand schizophrenia
Valéria de Almeida, Daniel Martins‐de‐Souza
European Archives of Psychiatry and Clinical Neuroscience (2018) Vol. 268, Iss. 7, pp. 727-737
Closed Access | Times Cited: 19
Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice
Marta Kruk-Słomka, Izabela Banaszkiewicz, Tomasz Słomka, et al.
Molecular Neurobiology (2019) Vol. 56, Iss. 11, pp. 7251-7266
Open Access | Times Cited: 19
Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model
Alexandre Seillier, Alex Martinez, Andrea Giuffrida
PLoS ONE (2020) Vol. 15, Iss. 3, pp. e0230238-e0230238
Open Access | Times Cited: 17
The role of the endocannabinoid system as a therapeutic target for autism spectrum disorder: Lessons from behavioral studies on mouse models
Susanna Pietropaolo, Giovanni Marsicano
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 664-678
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top